Last reviewed · How we verify
New regimen(BdqCfzLzd+XY)
This is a combination regimen of bedaquiline, clofazimine, linezolid, and two additional agents (XY) designed to treat drug-resistant tuberculosis by targeting multiple mycobacterial pathways simultaneously.
This is a combination regimen of bedaquiline, clofazimine, linezolid, and two additional agents (XY) designed to treat drug-resistant tuberculosis by targeting multiple mycobacterial pathways simultaneously. Used for Drug-resistant tuberculosis (MDR-TB and XDR-TB).
At a glance
| Generic name | New regimen(BdqCfzLzd+XY) |
|---|---|
| Also known as | New regimen for NTM-PD(BdqCfzLzd+XY) |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Drug class | Antituberculous combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The regimen combines bedaquiline (ATP synthase inhibitor), clofazimine (redox-active agent), and linezolid (protein synthesis inhibitor) with two unspecified agents (XY) to provide synergistic activity against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis. This multi-drug approach aims to overcome resistance mechanisms and improve treatment outcomes in difficult-to-treat TB cases.
Approved indications
- Drug-resistant tuberculosis (MDR-TB and XDR-TB)
Common side effects
- Peripheral neuropathy
- Hepatotoxicity
- QT prolongation
- Gastrointestinal disturbances
- Photosensitivity (clofazimine)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |